Gene · 5692
PSMB4: proteasome 20S subunit beta 4
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PSMB4: proteasome 20S subunit beta 4. Genes, record 5692. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5692
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P28070 | Proteasome subunit beta type-4 | 264 | 150 | Ensembl, GeneID, HGNC |
Source UniProt
Patents28
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 59533 | P28070 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 3433 | P28070 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 4702 | P28070 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 3433 | P28070 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 4702 | P28070 | Espacenet |
| US 11827937 B2 | 2023-11-28 | 82 | P28070 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 67913 | P28070 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 170884 | P28070 | Espacenet |
| JP 2022033877 A | 2022-03-02 | 3641 | P28070 | Espacenet |
| JP 2022033878 A | 2022-03-02 | 3641 | P28070 | Espacenet |
1 to 10 of 28
See all 28 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BORTEZOMIB | CHEMBL325041 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| BORTEZOMIB D-MANNITOL | CHEMBL5315122 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| CARFILZOMIB | CHEMBL451887 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB | CHEMBL2141296 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB CITRATE | CHEMBL3545432 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| MARIZOMIB | CHEMBL371405 | 20S proteasome inhibitor | INHIBITOR | ChEMBL |
| OPROZOMIB | CHEMBL2103884 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
Trials1,241
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07605416 | CARFILZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07601100 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07600151 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07513129 | BORTEZOMIB | PHASE1 | ClinicalTrials.gov | |
| NCT07479979 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07464210 | BORTEZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07463807 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07428369 | BORTEZOMIB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | BORTEZOMIB | PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | CARFILZOMIB | PHASE3 | ClinicalTrials.gov |
1 to 10 of 1,241
See all 1,241 trialsNIH grants771
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PSMB4 papers | Newest fiscal year |
|---|---|---|---|
| ZIAAI001220 | Pathogenesis, and Outcome of Autoinflammatory Diseases, NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still's-like Diseases, and other Undifferentiated Autoinflammatory Diseases | 8 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 6 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 6 | 2025 |
| ZIAHG200372 | Genetics, Pathophysiology, and Treatment of Autoinflammatory and Autoimmune Diseases | 4 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 3 | 2025 |
| P50CA186781 | Mayo Clinic Multiple Myeloma SPORE | 3 | 2025 |
| ZIAAI000646 | Transgenic Animal Models Of Human Immune Defects | 3 | 2025 |
| ZIAAI000647 | Genes And Gene Products As Immunoadjuvants | 3 | 2025 |
| ZICES102445 | Gene Expression and Microarrays | 3 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 2 | 2025 |
1 to 10 of 771Source NIH's project files
See all 771 nih grantsPapers807
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A multi-region transcriptomic framework reveals global and region-specific ubiquitin-proteasome system biomarkers in Alzheimer's disease. | Funct Integr Genomics | 2026 | 42809130 | PubTator, text mining | PubMed |
| SADS-CoV Nsp1 hijacks proteasomal subunits to degrade IRF1. | Vet Microbiol | 2026 | 42721780 | PubTator, text mining | PubMed |
| Machine learning-driven QSAR modeling combined with single cell transcriptomics identifies novel drug targets for lung cancer. | J Transl Med | 2026 | 42321836 | PubTator, text mining | PubMed |
| Extracellular Vesicle-Mediated Nucleolin Transfer in Glioblastoma: A Targetable Axis Driving Blood-Tumour Barrier Formation. | J Extracell Vesicles | 2026 | 41926335 | PubTator, text mining | PubMed |
| Sarcomatoid Renal Cell Carcinoma: Biological Features and Therapeutic Implications-A Narrative Review. | Curr Urol Rep | 2026 | 41792526 | PubTator, text mining | PubMed |
| Optimization of potential targets for antidepressant Chinese medicines: AI and multi-omics methods. | Chin Med | 2026 | 41668206 | PubTator, text mining | PubMed |
| Reduced Proteasome Degradation of HSF-1 Shifts Protein Stress Management With Age in Caenorhabditis elegans. | Aging Cell | 2026 | 41612742 | PubTator, text mining | PubMed |
| Distant metastases of melanoma exhibit varying extent of intrapatient proteogenomic heterogeneity. | Clin Transl Med | 2025 | 41017066 | PubTator, text mining | PubMed |
| Mechanistic insights into aristolochic acid-induced hepatocellular carcinoma: a multi-dimensional analysis integrating network toxicology, machine learning, and molecular dynamics simulation. | Toxicon | 2025 | 40921337 | PubTator, text mining | PubMed |
| Predictive value of MHC-related genes in cervical cancer: implications for immunotherapy and prognostic nomogram development. | Discov Oncol | 2025 | 40888998 | PubTator, text mining | PubMed |
1 to 10 of 807
See all 807 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5692
GET https://conductscience.org/api/genes/v1/5692/patents?page=2